Key result
Early detection and management of cardiac comorbidities in cirrhosis enhance post-transplant CV outcomes.
Why the study?
Cardiac comorbidities in patients with cirrhosis are common yet frequently under-recognised, with cirrhotic cardiomyopathy and concomitant coronary artery disease contributing to adverse events and posing significant management challenges.
This review underscores the critical need for early detection and management of cardiac comorbidities, such as cirrhotic cardiomyopathy and coronary artery disease, in patients with cirrhosis to improve liver transplantation outcomes.
Supports pre-transplant cardiac screening in cirrhosis; leaves open whether early intervention improves survival in prospective studies.
Cardiac comorbidities in patients with cirrhosis are common yet frequently under-recognised. Cirrhotic cardiomyopathy, a subclinical state of cardiac dysfunction, is emerging as a critical contributor to major adverse cardiac events in this patient population, as well as liver events such as hepatorenal syndrome. The increasing prevalence of patients with metabolic dysfunction-associated steatotic liver disease and concomitant coronary artery disease also poses significant management challenges for these patients. This review focuses on the considerable burden of cardiac disease in patients with cirrhosis, most notably in those undergoing assessment for liver transplantation. Our findings highlight the importance of early detection and the use of appropriate management strategies to enhance post-transplant cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Brick et al. (2025) conducted a review in Cirrhosis and cardiac comorbidities. Early detection and management of cardiac comorbidities in patients with cirrhosis are critical to enhance post-transplant cardiovascular outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: